Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

With a market cap of $151.2 billion, Amgen Inc. (AMGN) is a leading American biotechnology company headquartered in Thousand ...

Amgen’s adjusted earnings per share reached $4.90, exceeding expectations and marking a 24% increase year-over-year. Total ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.

Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic challenges.

Amgen (NASDAQ:AMGN) reported a 24% rise in first-quarter profit, fueled by strong product sales, while reaffirming full-year ...

Q1 2025. Management View. CEO Robert Bradway emphasized a strong start to 2025, highlighting 9% year-over-year revenue growth and 14% vol ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...